ASSESSMENT OF DYSLIPIDEMIA AND OTHER CARDIOVACULAR RISK FACTORS IN PATIENTS WITH MYCOSIS FUNGOIDES AND LICHIN PLANUS

Hoda G.Bakr; Fatma Eldesouky; Abdulla M Esawy; Safaa M. El Alawi

Volume : V, Issue : VIII, August - 2016

ASSESSMENT OF DYSLIPIDEMIA AND OTHER CARDIOVACULAR RISK FACTORS IN PATIENTS WITH MYCOSIS FUNGOIDES AND LICHIN PLANUS

Hoda G. Bakr, Fatma Eldesouky, Abdulla M Esawy, Safaa M. El Alawi

Abstract :

Background: Coronary heart disease has been the leading cause of death in developed and developing nations .Study the association between mycosis fungoides (MF)and lichen planus(LP)as cardiovascular risk factors can decrease the mortality from cardiovascular disease. We aimed to assess the dyslipidemia and other cardiologic risk factors in patients suffering from mycosis fungoides and lichen planus. Subjects and methods: 30 patients with mycosis fungoides, 30 patients with lichen planus(they did not start treatment)and 20 age and gender matched healthy subjects were included in the study. The diagnosis was made through clinical picture and was confirmed by skin biopsy. Weight, height and body mass index (BMI) were measured, also we assessed routine laboratory tests, serum total cholesterol, high–density lipoprotein cholesterol, low–density lipoprotein cholesterol, triglyceride, fasting blood glucose, homocysteine and high sensitivity C– reactive protein .Results: There was no significant difference in age, gender ,weight, height and BMI between studied subjects . Serum total cholesterol , LDL levels and LDL–C/HDL–C ratio, homocysteine and high sensitivity C– reactive protein were significantly elevated in patients with MF &LP compared to control. Fasting blood glucose ,HDL and triglycerides did not differ between patients and control . Percentage of dyslipidemia in MF and LP patients were significantly elevated. Conclusions: Mycosis fungoides and LP are association with dyslipidemia and risks of cardiovascular disease, which should be investigated and followed up for earlier diagnosis and proper managements to decrease the cardiovascular comorbidities, and improve patients‘ long–term outcome.